• linkedin
  • Increase Font
  • Sharebar

    Drugs in Perspective: Aptiom (eslicarbazepine acetate)

    Seizures are recognized as the result of a brain problem and can occur as a result of the appearance of abnormal electrical activity in the human brain.1 The image that is normally conjured up when people think of seizures are sudden convulsive or involuntary contractions that can vary from mild to severe. Seizures can be categorized as focal seizures (partial seizures) or generalized seizures.1,2 Seizures are associated with a variety of causes, such as fevers, medications, head injuries, and particular diseases. Individuals who suffer from recurrent seizures as a result of a brain disorder have epilepsy that can be characterized by an enduring predisposition to generate these types of seizures.2,3

    Aptiom (eslicarbazepine acetate) is an oral antiepileptic tablet that was approved by FDA on November 8, 2013, as an add-on medication to treat seizure disorders that can be associated with epilepsy.4,5 The precise mechanism of action of Aptiom has not been explained, but it is believed to involve the inhibition of voltage-gated sodium channels.5

    It is available in tablet strengths of 200 mg, 400 mg, 600 mg, and 800 mg.5 The dose of Aptiom is typically started at 400 mg once daily and after a week of therapy, the dose can be increased to 800 mg once daily, which is considered to be the recommended maintenance dose.6 In patients with moderate-to-severe renal impairment (creatinine clearance [CrCl] <50 mL/min) the initial dose is 200 mg once daily and after 2 weeks the dose can be increased to 400 mg once daily with a maximum dose of 600 mg once daily.6 No dosage adjustment is necessary in patients with mild-to-moderate hepatic impairment.6

    Relevance

    Aptiom is recognized as a novel molecular entity or a unique active ingredient, which makes it structurally distinctive from other drugs.7 It is able to undergo fast and complete hydrolysis to eslicarbazepine, which is the metabolite that is believed to be largely responsible for producing its therapeutic effect.8

    Epilepsy agents in the pipelineClick to enlarge

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available